Display all Bios

John V. Talley
President and Chief Executive Officer

John V. Talley has been our President, Chief Executive Officer and a Director since October 2001. Mr. Talley has more than 23 years of experience in the pharmaceutical industry. Prior to joining us, Mr. Talley was the Chief Executive Officer of Consensus Pharmaceuticals, a biotechnology drug discovery start-up company that developed a proprietary peptide-based combinatorial library screening process. Prior to joining Consensus, Mr. Talley led Penwest Ltd.'s efforts in its spin-off of its subsidiary Penwest Pharmaceuticals Co. in 1998 and served as President and Chief Operating Officer of Penwest Pharmaceuticals. Mr. Talley started his career at Sterling Drug Inc., where he was responsible for all U.S. marketing activities for prescription drugs, helped launch various new pharmaceutical products and participated in the 1988 acquisition of Sterling Drug by Eastman Kodak Co. Mr. Talley received his B.S. in Chemistry from the University of Connecticut and completed coursework towards an M.B.A. in Marketing from New York University, Graduate School of Business.

Robert W. Cook
Chief Financial Officer and Senior Vice President, Finance and Administration

Robert W. Cook has been our Chief Financial Officer and Senior Vice President, Finance and Administration since April 2004. Prior to joining us, Mr. Cook was Vice President, Finance and Chief Financial Officer of Pharmos Corporation since January 1998 and became Executive Vice President of Pharmos in February 2001. From May 1995 until his appointment as Pharmos's Chief Financial Officer, he was a vice president in GE Capital's commercial finance subsidiary, based in New York. From 1977 until 1995, Mr. Cook held a variety of corporate finance and capital markets positions at The Chase Manhattan Bank, both in the United States and in several overseas locations. He was named a managing director of Chase and several of its affiliates in January 1986. Mr. Cook received his B.S. in International Finance from The American University, Washington, D.C.

Charles Darder
Controller and Vice President of Finance and Administration

Charles Darder has been our Corporate Controller since January 2007. Prior to joining us, Mr. Darder was the Director of Finance for Bradley Pharmaceuticals since May 2006. Prior to that Mr. Darder was with Memory Pharmaceuticals since May 2000 in various finance positions. From 1993 until 2000, Mr. Darder held a variety of corporate finance positions at The Prudential, Con Edison and The McGraw-Hill Companies. Mr. Darder received his B.S. in Public Accounting from Pace University, Pleasantville, NY and is a Certified Public Accountant.

Dileep Bhagwat , Ph.D., MBA
Senior Vice President of Pharmaceutical Development

Dileep Bhagwat, Ph.D., M.B.A., has been our Senior Vice President of Pharmaceutical Development since February 2004 and has more than 20 years of pharmaceutical experience developing and commercializing various dosage forms. Prior to joining EpiCept in 2004, Dr. Bhagwat worked at Bradley Pharmaceuticals, as Vice President, Research and Development and Chief Scientific Officer. From November 1994 through September 1999, Dr. Bhagwat was employed at Penwest Pharmaceuticals in various capacities, including Vice President, Scientific Development and Regulatory Affairs and at Purdue Frederick Research Center as Assistant Director of Pharmaceutical Development. Dr. Bhagwat holds many U.S. and foreign patents and has presented and published on dosage form development and drug delivery. Dr. Bhagwat holds a B.S. in Pharmacy from Bombay University, an M.S. and Ph.D. in Industrial Pharmacy from St. John's University in New York and an M.B.A. in International Business from Pace University in New York.

Ben Tseng , Ph.D.
Chief Scientific Officer

Ben Tseng, Ph.D., has been EpiCept's Chief Scientific Officer since January 2006. Prior to its merger with EpiCept in 2006, Dr. Tseng served as Vice President, Research of Maxim Pharmaceuticals, Inc. Dr. Tseng previously served as Vice President, Biology for Cytovia, Inc, which he joined in 1998. From 1995 to 1998 Dr. Tseng served as Director, Therapeutic Biology at Chugai Biopharmaceutical, Inc. and from 1989 to 1995 as Scientific Director, Biology at Genta Inc. Prior to joining Genta, Dr. Tseng was a tenured Associate Adjunct Professor in the Department of Medicine, faculty member of Physiology and Pharmacology Program, and Associate Member of the Cancer Center at the University of California, San Diego. Dr. Tseng received a B.A. in Mathematics from Brandeis University and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University.

Michael Chen, SM, MBA
Vice President, Global Business Development

Michael Chen joined EpiCept in May 2006 as Vice President for Global Business Development. Prior to joining us, Mr. Chen was the Executive Vice President for Sales and Marketing with the SpyGlass Group, a healthcare consulting firm. From 1995 to 2004, Mr. Chen was the Executive Director, Worldwide Licensing and Acquisitions for Johnson & Johnson. Prior to that position, Mr. Chen was the Vice President for Business Development with Synaptic Pharmaceutical Corporation from 1993 to 1995 and the Director - Business Development with CIBA-Geigy from 1985 to 1993. Mr. Chen received his MBA from Harvard Business School, an S.M. in chemical engineering from the Massachusetts Institute of Technology and a B.S. in chemical engineering (with distinction) from Cornell University.

Stephane Allard, M.D.
Chief Medical Officer

Dr. Allard was formerly Chief Executive Officer, President, and a Director of Biovest International. Prior to joining Biovest, Dr. Allard was Vice President of Medical Affairs of the US affiliate of Sanofi-Synthelabo, a multi-billion dollar global pharmaceutical company and was responsible for the medical strategy of products such as Plavix®, Ambien ®, Avapro®, and Eloxatin®. Dr. Allard served as President of Synthelabo, Inc. and Director of Research and Development at Lorex Pharmaceuticals, where he was responsible for the development of Ambien® and the start up of Synthelabo, Inc in the US. He led the clinical activities for products such as Ambien®, Kerlone® and Uroxatral® and the liaison efforts with the FDA. He served as European Clinical Director of Clinical Research for Synthelabo (Paris). Dr. Allard received his medical doctorate from Rouen Medical College and received a Diplomate of CESAM (Certificate of Statistical Studies Applied to Medicine) and a PhD in Clinical Pharmacology and Pharmacokinetics (Pitie Salpetriere Hosp.); Paris, France.